Bispecifics move beyond cancer
Hitting two targets with one molecule is all the rage in oncology, but Roche and others have taken this work into other disease areas.
J&J’s $5bn projects have much to prove
The group highlighted Carvykti, nipocalimab and milvexian among its potential mega-blockbusters.
Philips draws a line under its sleep nightmare
The group has finally revalued its troubled sleep franchise. So what now?
